Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-19.91M | $-95.20 |
| 2024 | $0.00 | $-22.14M | $-571.20 |
| 2023 | $0.00 | $-29.22M | $-3321.76 |
| 2022 | $45.0K | $-25.43M | $-5740.80 |
| 2021 | $449.0K | $-10.93M | $226.56 |
Social Signal Score
Earnings
Tue, Nov 17(in 3 months)
Typical surprise -3.6% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Mar 27$-0.57 vs $-1.56beat
- Tue, Nov 11$-2.21 vs $-1.68miss
- Tue, Aug 12$-1.99 vs $-1.92miss
- Tue, May 13$-2.16 vs $-1.80miss
- Fri, Apr 4$-4.32 vs $-5.92beat
Estimates and results for CLDI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
CLDIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·1d ago·Neutral
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027
View source ↗